Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy
Oncology · 2025
DOI: 10.1159/000546856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Francesco Vitiello und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Introduction
Patients with biliary tract cancers (BTCs) often require antibiotic therapy before starting systemic treatment that includes an immune checkpoint inhibitor. This study aimed to evaluate the prognostic impact of antibiotic therapy administered in the 15 days prior to the start of chemoimmunotherapy in patients with BTC.
Methods
The study population included patients with metastatic or locally advanced BTC from Western and Eastern populations treated with first-line chemoimmunotherapy. The aim of the study was to evaluate the impact of antibiotic therapy in the 15 days prior to starting oncological treatment (AT population) compared to patients who did not receive antibiotic therapy (NAT). Univariate and multivariate analyses were used to evaluate predictive factors for overall survival (OS) and progression-free survival (PFS), while prognostic factors were analyzed by univariate and multivariate analysis using Cox regression model.
Results
A total of 666 patients were enrolled in the study: 93 (14%) in AT cohort and 573 (86%) in NAT cohort. In the AT population, the incidence of cholangitis (p = 0.0017), alanine aminotransferase elevation (p = 0.0009), fever (p = 0.0021), decreased appetite (p = 0.0007), itching (p = 0.0081), and rash (p = 0.012) was significantly higher compared to the NAT. The median OS was 15.9 months (95% confidence interval [CI]: 13.8–18.3) in NAT cohort versus 10.1 months (95% CI: 7.9–12.4) in AT cohort (NAT vs. AT, hazard ratio [HR]: 0.43, 95% CI: 0.27–0.70, p = 0.0006), while median PFS was 8.5 months in NAT cohort versus 5.4 months in AT cohort (NAT vs. AT, HR: 0.49, 95% CI: 0.34–0.71, p = 0.0001). Multivariate analysis confirmed the prognostic role of antibiotic for OS and PFS. Finally, NAT cohort showed better overall response rate compared with AT cohort (31.4% vs. 20.4%, p = 0.03).
Conclusions
The use of antibiotic therapy in the 15 days prior to starting chemoimmunotherapy is an independent unfavorable prognostic factor for survival in our cohort of patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
- Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
- Hannover Medical School, Hannover, Germany.
- Clinical Oncology Unit, Careggi University Hospital, Florence, Italy.
Zitieren
APA
Vitiello, F., Vivaldi, C., Rimini, M., Prinzi, F. L., Rizzato, M. D., Saborowski, A., Antonuzzo, L., Rossari, F., Satake, T., Peeters, F., Salani, F., Pressiani, T., Lucchetti, J., Kim, J. W., Abidoye, O., Rapposelli, I. G., Gallio, C., Tamberi, S., Finkelmeier, F., …, & Tesini, G. (2025). Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy. Oncology. https://doi.org/10.1159/000546856
Vancouver
Vitiello F, Vivaldi C, Rimini M, Prinzi FL, Rizzato MD, Saborowski A, et al. Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy. Oncology. 2025. doi:10.1159/000546856
BibTeX
@article{Vitiello2025,
author = {Vitiello, Francesco and Vivaldi, Caterina and Rimini, Margherita and Prinzi, Federica Lo and Rizzato, Mario Domenico and Saborowski, Anna and Antonuzzo, Lorenzo and Rossari, Federico and Satake, Tomoyuki and Peeters, Frederik and Salani, Francesca and Pressiani, Tiziana and Lucchetti, Jessica and Kim, Jin Won and Abidoye, Oluseyi and Rapposelli, Ilario Giovanni and Gallio, Chiara and Tamberi, Stefano and Finkelmeier, Fabian and Giordano, Guido and Pircher, Chiara and Chon, Hong Jae and Braconi, Chiara and Qaisar, Aitzaz and Pastorino, Alessandro and Castet, Florian and Tamburini, Emiliano and Yoo, Changhoon and Parisi, Alessandro and Diana, Anna and Scartozzi, Mario and Prager, Gerald W and Avallone, Antonio and Schirripa, Marta and Kim, Il Hwan and Perkhofer, Lukas and Oneda, Ester and Verrico, Monica and Couto, Nuno and Adeva, Jorge and Chan, Stephen Lam and Spinelli, Gian Paolo and Personeni, Nicola and Garajova, Ingrid and Rodriguez, Maria Grazia and Leo, Silvana and Alvim, Cecilia Melo and Roque, Ricardo and Farinea, Giovanni and Genovesi, Virginia and De Rosa, Antonio and Lavacchi, Daniele and Camera, Silvia and Ikeda, Masafumi and Dekervel, Jeroen and Niger, Monica and Balsano, Rita and Tonini, Giuseppe and Kang, Minsu and Tesini, Giulia},
title = {Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy},
journal = {Oncology},
year = {2025},
doi = {10.1159/000546856}
}
EUVIMED